Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 20, 2025

LAPC-4

RRID:CVCL_4744
Type: Cell Line

Proper Citation

(RRID:CVCL_4744)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_4744

Proper Citation: (RRID:CVCL_4744)

Sex: Male

Defining Citation: PMID:9095173, PMID:10861745, PMID:11304728, PMID:12725112, PMID:14518029, PMID:14518030, PMID:15486987, PMID:15643173, PMID:21698104, PMID:21750403, PMID:25960936, PMID:28145883, PMID:29194687, PMID:29739788, PMID:34402095

Comments: Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: Deep quantitative phosphoproteome analysis., Omics: Array-based CGH., Karyotypic information: Has lost chromosome Y., Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (PubMed=21698104; PubMed=21750403)., Group: Patented cell line.

Category: Cancer cell line

Name: LAPC-4

Synonyms: LAPC4, Los Angeles Prostate Cancer-4

Cross References: BTO:BTO_0002997, EFO:EFO_0005392, ATCC:CRL-13009, BioSample:SAMN03471350, cancercelllines:CVCL_4744, ChEMBL-Cells:CHEMBL3308023, ChEMBL-Targets:CHEMBL613292, Cosmic:1330913, Cosmic:1689711, Cosmic:2537793, Cosmic:2580299, GEO:GSM91931, GEO:GSM648820, GEO:GSM1374616, GEO:GSM1633305, GEO:GSM1633306, GEO:GSM1633307, GEO:GSM2069506, GEO:GSM2069507, GEO:GSM2069508, GEO:GSM2069509, GEO:GSM2069510, GEO:GSM2069511, GEO:GSM2069512, GEO:GSM2069513, GEO:GSM2649999,

GEO:GSM2650000, GEO:GSM2650001, GEO:GSM2650002, GEO:GSM2650003, GEO:GSM2650004, GEO:GSM3145715, GEO:GSM5402198, IARC_TP53:18889, PRIDE:PXD006561, Progenetix:CVCL_4744, PubChem_Cell_line:CVCL_4744, Wikidata:Q29565860

ID: CVCL_4744

Record Creation Time: 20250131T201207+0000

Record Last Update: 20250131T202731+0000

Ratings and Alerts

No rating or validation information has been found for LAPC-4.

Warning: Discontinued: ATCC; CRL-13009
Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: Deep quantitative phosphoproteome analysis., Omics: Array-based CGH., Karyotypic information: Has lost chromosome Y., Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (PubMed=21698104; PubMed=21750403)., Group: Patented cell line. Warning: Discontinued: ATCC; PTA-1441
Omics: Transcriptome analysis by RNAseq., Omics: Transcriptome analysis by microarray., Omics: Deep quantitative phosphoproteome analysis., Omics: Array-based CGH., Karyotypic information: Has lost chromosome Y., Virology: Contains an integrated xenotropic MuLV-related virus (XMRV) Bxv-1 (PubMed=21698104; PubMed=21750403)., Group: Patented cell line.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 25 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Frei K, et al. (2024) Inhibition of the Cyclin K-CDK12 complex induces DNA damage and increases the effect of androgen deprivation therapy in prostate cancer. International journal of cancer, 154(6), 1082.

Colucci M, et al. (2024) Retinoic acid receptor activation reprograms senescence response

and enhances anti-tumor activity of natural killer cells. Cancer cell.

Gui F, et al. (2024) Acute BRCAness Induction and AR Signaling Blockage through CDK12/7/9 Degradation Enhances PARP Inhibitor Sensitivity in Prostate Cancer. bioRxiv : the preprint server for biology.

Vellky JE, et al. (2024) ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity Signature. Clinical cancer research : an official journal of the American Association for Cancer Research, 30(8), 1530.

Calì B, et al. (2024) Coagulation factor X promotes resistance to androgen-deprivation therapy in prostate cancer. Cancer cell, 42(10), 1676.

Gonthier K, et al. (2023) Isocitrate dehydrogenase 1 sustains a hybrid cytoplasmic-mitochondrial tricarboxylic acid cycle that can be targeted for therapeutic purposes in prostate cancer. Molecular oncology.

Allen SG, et al. (2023) Impact of sequencing of androgen receptor-signaling inhibition and radiotherapy in prostate cancer: importance of homologous recombination disruption. World journal of urology, 41(12), 3877.

Zhang A, et al. (2023) Concurrent Targeting of HDAC and PI3K to Overcome Phenotypic Heterogeneity of Castration-resistant and Neuroendocrine Prostate Cancers. Cancer research communications, 3(11), 2358.

Pan M, et al. (2023) Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy. Cancer research communications, 3(7), 1378.

Wang H, et al. (2023) Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer. Cancer cell, 41(7), 1345.

Sperger JM, et al. (2023) Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(12), 2324.

Rodems TS, et al. (2022) Reversible epigenetic alterations regulate class I HLA loss in prostate cancer. Communications biology, 5(1), 897.

Jain S, et al. (2022) Metabolic targeting of cancer by a ubiquinone uncompetitive inhibitor of mitochondrial complex I. Cell chemical biology, 29(3), 436.

Cordova RA, et al. (2022) GCN2 eIF2 kinase promotes prostate cancer by maintaining amino acid homeostasis. eLife, 11.

Kuznik NC, et al. (2022) A chemical probe for BAG1 targets androgen receptor-positive prostate cancer through oxidative stress signaling pathway. iScience, 25(5), 104175.

Csizmarik A, et al. (2022) Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer. International journal of cancer, 151(8), 1405.

Cui C, et al. (2021) Neutrophil elastase selectively kills cancer cells and attenuates tumorigenesis. Cell, 184(12), 3163.

Xiao Z, et al. (2021) AXL cooperates with EGFR to mediate neutrophil elastase-induced migration of prostate cancer cells. iScience, 24(11), 103270.

Jillson LK, et al. (2021) MAP3K7 Loss Drives Enhanced Androgen Signaling and Independently Confers Risk of Recurrence in Prostate Cancer with Joint Loss of CHD1. Molecular cancer research : MCR, 19(7), 1123.